verified SJR 0,722 · Q2 • database Scopus / SJR & Web of Science indexed

United Arab Emirates · Bentham Science Publishers

workspace_premium Q2 — Drug Discovery lock Subscription

Current Cancer Drug Targets

Current Cancer Drug Targets is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 106. It has an SJR impact factor of 0,722 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,722.

ISSN: 1568-0096

Publisher: Bentham Science Publishers

Category: Drug Discovery

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,722 Q2

H-index 106

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,722

H-index

106

Docs (year)

109

Docs 3y

217

Total refs

8069

Cites 3y

592

Citable 3y

211

Cites/Doc 2y

3.03

Ref/Doc

74.03

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Author Index To Volume 6

Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature

CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer

Costimulation, Coinhibition and Cancer

Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

Chronic Vaccination with a Therapeutic EGF-Based Cancer Vaccine: A Review of Patients Receiving Long Lasting Treatment

Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance

Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)

Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?

Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives

Budesonide and Phenethyl Isothiocyanate Attenuate DNA Damage in Bronchoalveolar Lavage Cells of Mice Exposed to Environmental Cigarette Smoke

SHOW MORE ARTICLES

Bioactive Albumin-Based Carriers for Tumour Chemotherapy

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor

Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review

Anticancer Immunotherapy in Combination with Proapoptotic Therapy

Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic

Anti-Invasive and Anti-Metastasis Strategies: New Roads, New Tools and New Hopes

Anatomic Site-Related Expression of Cancer-Associated Molecules in Ovarian Carcinoma

An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein

AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1

Advances in Nano Drugs for Cancer Chemotherapy

ADAM Proteins- Therapeutic Potential in Cancer

Active-Targeted Nanotherapy Strategies for Prostate Cancer

FAQs

Current Cancer Drug Targets has an SJR of 0,722 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Current Cancer Drug Targets is 25%.

Current Cancer Drug Targets

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Current Cancer Drug Targets?

What is the APC / publication cost?

What is the acceptance rate?